|
Mar 13
|
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
|
|
Mar 12
|
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
|
|
Mar 10
|
Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Feb 26
|
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
|
|
Feb 26
|
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Feb 23
|
Dr. Gregory George MD PhD Joins Mesoblast Board
|
|
Feb 19
|
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
Exploring 3 High Growth Tech Stocks In Australia
|
|
Oct 19
|
Mesoblast Advances Cellular Medicines Amid FDA Hopes
|
|
Oct 10
|
ASX Growth Companies With High Insider Ownership In October 2024
|
|
Oct 9
|
3 ASX Growth Companies With Insider Ownership Up To 37%
|
|
Jul 23
|
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
|
|
Jul 23
|
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
|
|
May 24
|
ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%
|
|
May 23
|
ASX Growth Leaders With High Insider Ownership To Watch
|
|
Jan 31
|
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
|
|
Jan 19
|
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
|
|
Dec 21
|
5 Stocks to Ride the Santa Claus Rally
|
|
Aug 31
|
Mesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call Transcript
|